| Medical and Biological Laboratories Co., Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110293618 | ANTI-HUMAN CLCP1 ANTIBODY AND USE THEREOF - The present invention provides novel antibodies that recognize the extracellular domain of a human CLCP1 antigen; nucleic acids encoding the antibodies; vectors carrying the nucleic acids in an expressible manner; transformed cells containing the vectors; methods for producing the antibodies; diagnostic methods for cancer or prognosis of cancer, immunohistological or immunocytological assay methods, and kits for determining the expression level of CLCP1 in cells or tissues, all of which use the antibodies; pharmaceutical compositions comprising the antibodies; agents for treating or preventing CLCP1-expressing cancer; agents for inhibiting growth, migration, invasion, or metastasis of CLCP1-expressing cancer cells; immunostaining agents for staining CLCP1-expressing cancer cells; and agents for treating or preventing CLCP1-expressing tumor. The present invention also provides methods of screening for candidate substances that inhibit cancer cell growth, invasion, migration, or metastasis, or candidate substances having cytotoxicity against cancer cells. | 12-01-2011 |
| 20110014626 | METHODS FOR MEASURING THE INSULIN RECEPTOR ALPHA SUBUNIT - Presence of free insulin receptor α-subunit in blood was discovered. Furthermore, methods for measuring the insulin receptor α-subunit was provided, the method comprising the steps of contacting the insulin receptor α-subunit in a blood sample with an antibody recognizing the insulin receptor α-subunit, and detecting the binding between the two. Measurement of the free insulin receptor α-subunit in the blood is useful for evaluating risk factors for diabetes. | 01-20-2011 |
| 20090305324 | CYTOTOXIC T-CELL EPITOPE PEPTIDES THAT SPECIFICALLY ATTACK EPSTEIN-BARR VIRUS-INFECTED CELLS AND USES THEREOF - The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells. | 12-10-2009 |
| 20090280511 | Methods for selecting candidate peptides presented on the surface of cancer cells following their binding to MHC class I molecules - An objective of the present invention is to provide methods for selecting candidate peptides presented on the surface of cancer cells following binding to MHC class I molecules, wherein the peptides are involved in the stimulation of T cell immunity (cellular immunity). The present inventors discovered a new principle of MHC I-mediated antigen presentation in which a T cell antigen epitope is more efficiently presented on MHC I molecules when it is positioned at the N-terminal side than when positioned at the C-terminal side. | 11-12-2009 |
| 20090142363 | CYTOTOXIC T-CELL EPITOPE PEPTIDE AND USE THEREOF - The successful identification of epitope peptides specific to adenovirus belonging to subgroup B and epitope peptides exhibiting specificity to all adenoviruses using hexon proteins which exhibit the highest homology among genes of adenoviruses of various subgroups is herein described. The peptides have a function capable of efficiently inducing adenovirus-specific cytotoxic T cells (CTLs). Thus, the peptides disclosed herein find utility as vaccines for active immunization. Furthermore, CTLs induced by such peptides find utility as passive immunotherapeutic agents. | 06-04-2009 |
| 20080248011 | Methods for Isolating Monocytes - The present invention provides HIDE1 as novel monocyte markers. Since HIDE1 are membrane proteins, monocytes can be specifically detected by using antibodies that bind to HIDE1. Further, HIDE1-positive monocytes can also be collected from peripheral blood or the like using a cell sorter, magnet, or such. Monocytes that can be prepared based on the present invention are useful in cell immunotherapy. | 10-09-2008 |
